GlassScriptPhysician profile
Raymond V Romano
NPI 1134325178
$1,466.01
in general payments reported to CMS, 2019-2025
24 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $12.89 · 2021: $242 · 2022: $208 · 2023: $242 · 2024: $382 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $173.78 | 2021-2024 | Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.45 | 2022-2024 | |
| Abbott Laboratories | $147.66 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Janssen Pharmaceuticals, INC | $146.38 | 2021-2023 | Spravato |
| Merck Sharp & Dohme LLC | $125.90 | 2019 | |
| Dexcom, INC. | $112.92 | 2022-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $82.96 | 2023-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $63.48 | 2021-2025 | |
| Amgen INC. | $61.44 | 2019-2025 | Otezla, Repatha |
| Astellas Pharma US INC | $57.37 | 2022-2024 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $49.55 | 2024-2025 | Shingrix, Arexvy, Rotarix |
| Novartis Pharmaceuticals Corporation | $38.14 | 2023 | |
| Medtronic, INC. | $36.64 | 2023-2024 | Intellis Adaptivestim, Venaseal |
| Dynavax Technologies Corporation | $27.90 | 2023-2025 | Heplisav-B |
| Lilly USA, LLC | $26.65 | 2022-2023 | Mounjaro |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.89 | 2025 | Xifaxan |
| Edwards Lifesciences Corporation | $20.71 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Inari Medical, INC. | $19.11 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bayer Healthcare Pharmaceuticals INC. | $17.52 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $17.46 | 2024 | Airsupra |
| Ascensia Diabetes Care US INC. | $17.10 | 2023 | |
| Inspire Medical Systems, INC. | $16.70 | 2025 | Inspire |
| Sanofi Pasteur INC. | $12.89 | 2020 | |
| Gt Medical Technologies, INC | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Romano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.